These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21518979)

  • 1. Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?
    Liao JK
    Circulation; 2011 May; 123(18):1925-8. PubMed ID: 21518979
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
    Seiki S; Frishman WH
    Cardiol Rev; 2009; 17(2):70-6. PubMed ID: 19367148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia.
    Stein EA; Bays H; O'Brien D; Pedicano J; Piper E; Spezzi A
    Circulation; 2011 May; 123(18):1974-85. PubMed ID: 21518985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
    Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging lipid-lowering drugs: squalene synthase inhibitors.
    Elsayed RK; Evans JD
    Expert Opin Emerg Drugs; 2008 Jun; 13(2):309-22. PubMed ID: 18537523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions.
    Shiomi M; Yamada S; Amano Y; Nishimoto T; Ito T
    Br J Pharmacol; 2008 Jul; 154(5):949-57. PubMed ID: 18587443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia.
    Burnett JR
    Curr Opin Investig Drugs; 2006 Sep; 7(9):850-6. PubMed ID: 17002264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel nonstatin strategies to lower low-density lipoprotein cholesterol.
    Davidson MH
    Curr Atheroscler Rep; 2009 Jan; 11(1):67-70. PubMed ID: 19080731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation.
    Rimondi E; Valencic E; Tommasini A; Secchiero P; Melloni E; Marcuzzi A
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
    Charlton-Menys V; Durrington PN
    Drugs; 2007; 67(1):11-6. PubMed ID: 17209661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice.
    Marcuzzi A; Loganes C; Celeghini C; Kleiner G
    Curr Med Chem; 2018; 25(24):2783-2796. PubMed ID: 28901277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squalene synthase inhibitors.
    Menys VC; Durrington PN
    Br J Pharmacol; 2003 Jul; 139(5):881-2. PubMed ID: 12839859
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes.
    Nishimoto T; Tozawa R; Amano Y; Wada T; Imura Y; Sugiyama Y
    Biochem Pharmacol; 2003 Dec; 66(11):2133-9. PubMed ID: 14609738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
    J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of nonstatin cholesterol lowering agents.
    Trapani L; Segatto M; Ascenzi P; Pallottini V
    IUBMB Life; 2011 Nov; 63(11):964-71. PubMed ID: 21990243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Primary prevention with statins, consensus and risk tables].
    Miguel García F; García Ortiz A; Montero Alonso MJ
    Aten Primaria; 2005 Jun; 36(1):31-8. PubMed ID: 15946613
    [No Abstract]   [Full Text] [Related]  

  • 18. [No documentation for overtreatment with statins].
    Jensen GB
    Ugeskr Laeger; 2011 Sep; 173(38):2363; author reply 2363. PubMed ID: 22034664
    [No Abstract]   [Full Text] [Related]  

  • 19. Statins as cardioprotective agents.
    Piskur JR; Stone NJ
    Am J Manag Care; 2002 Jun; 8(9 Suppl):25-9. PubMed ID: 12099325
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis.
    Miki T; Kori M; Mabuchi H; Tozawa R; Nishimoto T; Sugiyama Y; Teshima K; Yukimasa H
    J Med Chem; 2002 Sep; 45(20):4571-80. PubMed ID: 12238936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.